- Home
- Publications
- Publication Search
- Publication Details
Title
New Insights into Therapeutic Targets in Myeloma
Authors
Keywords
-
Journal
Hematology-American Society of Hematology Education Program
Volume 2011, Issue 1, Pages 184-190
Publisher
American Society of Hematology
Online
2011-12-08
DOI
10.1182/asheducation-2011.1.184
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Treatment Options for Relapsed and Refractory Multiple Myeloma
- (2011) Sagar Lonial et al. CLINICAL CANCER RESEARCH
- Genomics in Multiple Myeloma
- (2011) Nikhil C. Munshi et al. CLINICAL CANCER RESEARCH
- Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study
- (2011) Irene M Ghobrial et al. LANCET ONCOLOGY
- Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study
- (2011) Philippe Moreau et al. LANCET ONCOLOGY
- Initial genome sequencing and analysis of multiple myeloma
- (2011) Michael A. Chapman et al. NATURE
- Multiple Myeloma
- (2011) Antonio Palumbo et al. NEW ENGLAND JOURNAL OF MEDICINE
- A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma
- (2010) D. Chauhan et al. BLOOD
- Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma
- (2010) J. Rosenblatt et al. BLOOD
- Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma
- (2010) P. G. Richardson et al. BLOOD
- Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma
- (2010) G. Gorgun et al. BLOOD
- Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients
- (2010) A. Broyl et al. BLOOD
- Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma
- (2010) R. H. Prabhala et al. BLOOD
- PR-924, a selective inhibitor of the immunoproteasome subunit LMP-7, blocks multiple myeloma cell growth both in vitro and in vivo
- (2010) Ajita V. Singh et al. BRITISH JOURNAL OF HAEMATOLOGY
- Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: A Randomized Controlled Trial
- (2010) Antonio Palumbo et al. JOURNAL OF CLINICAL ONCOLOGY
- Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors
- (2010) M. de Weers et al. JOURNAL OF IMMUNOLOGY
- First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial
- (2010) Gareth J Morgan et al. LANCET
- Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study
- (2010) Michele Cavo et al. LANCET
- Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial
- (2010) María-Victoria Mateos et al. LANCET ONCOLOGY
- Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial
- (2010) Annemiek Broyl et al. LANCET ONCOLOGY
- Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study
- (2010) S K Kumar et al. LEUKEMIA
- Lenalidomide, melphalan, prednisone and thalidomide (RMPT) for relapsed/refractory multiple myeloma
- (2010) A Palumbo et al. LEUKEMIA
- Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM)
- (2010) M Q Lacy et al. LEUKEMIA
- Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity
- (2010) Douglas W McMillin et al. NATURE MEDICINE
- AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3β activation and RNA polymerase II inhibition
- (2010) L Santo et al. ONCOGENE
- The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition
- (2009) G. Bianchi et al. BLOOD
- Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma
- (2009) M. Fulciniti et al. BLOOD
- Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome
- (2009) F. Parlati et al. BLOOD
- Functional Interaction of Plasmacytoid Dendritic Cells with Multiple Myeloma Cells: A Therapeutic Target
- (2009) Dharminder Chauhan et al. CANCER CELL
- The Monoclonal Antibody nBT062 Conjugated to Cytotoxic Maytansinoids Has Selective Cytotoxicity Against CD138-Positive Multiple Myeloma Cells In vitro and In vivo
- (2009) H. Ikeda et al. CLINICAL CANCER RESEARCH
- Multicenter, Phase I, Dose-Escalation Trial of Lenalidomide Plus Bortezomib for Relapsed and Relapsed/Refractory Multiple Myeloma
- (2009) Paul G. Richardson et al. JOURNAL OF CLINICAL ONCOLOGY
- Pomalidomide (CC4047) Plus Low-Dose Dexamethasone As Therapy for Relapsed Multiple Myeloma
- (2009) Martha Q. Lacy et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic Significance of Copy-Number Alterations in Multiple Myeloma
- (2009) Hervé Avet-Loiseau et al. JOURNAL OF CLINICAL ONCOLOGY
- Design and Synthesis of an Orally Bioavailable and Selective Peptide Epoxyketone Proteasome Inhibitor (PR-047)
- (2009) Han-Jie Zhou et al. JOURNAL OF MEDICINAL CHEMISTRY
- Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial
- (2009) S Vincent Rajkumar et al. LANCET ONCOLOGY
- Prediction of Survival in Multiple Myeloma Based on Gene Expression Profiles Reveals Cell Cycle and Chromosomal Instability Signatures in High-Risk Patients and Hyperdiploid Signatures in Low-Risk Patients: A Study of the Intergroupe Francophone du Myélome
- (2008) Olivier Decaux et al. JOURNAL OF CLINICAL ONCOLOGY
- Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma
- (2008) I Breitkreutz et al. LEUKEMIA
- Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma
- (2008) Jesús F. San Miguel et al. NEW ENGLAND JOURNAL OF MEDICINE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started